Page 215 - DUOKOPT BIBLIOBOOK

EFFICACY

SECOND-LINE THERAPY WITH DORZOLAMIDE/TIMOLOL

OR LATANOPROST/TIMOLOL FIXED COMBINATION VERSUS

ADDING DORZOLAMIDE/TIMOLOL FIXED COMBINATION TO

LATANOPROST MONOTHERAPY

Konstas AG, et al. Br J Ophthalmol. 2008 Nov;92(11):1498-502

ABSTRACT

PURPOSE: To evaluate OAG patients, who were insufficiently controlled on latanoprost monotherapy,
to determine the 24h IOP efficacy and safety when changing them to DTFC or LTFC or adding DTFC.

METHODS: 3-month, prospective, observer-masked, placebo-controlled, crossover comparison. 31
adults with POAG or exfoliative glaucoma and mean baseline IOP >21 mm Hg on Latanoprost mo-
notherapy were randomised for 3 months to: DTFC, LTFC or DTFC and Latanoprost. Patients were
then crossed over to the next treatment for periods 2 and 3. At the end of the study, each patient had
received all 3 treatments in a randomized sequence.
IOP assessments : 24 h IOP monitoring.

STUDY CRITERIA: IOP (mmHg)

RESULTS: All treatments reduced the IOP individually from Latanoprost baseline for the 24 h pressure
curve (p < 0.0032).
There were no statistical differences between Dorzolamide/Timolol and Latanoprost/Timolol fixed
combinations.
Dorzolamide/Timolol fixed combination + Latanoprost tritherapy demonstrated a lower IOP versus
the other treatment groups.
The differences between groups were not significant for the mean 24 h fluctuation (p = 0.31).

Figure 13: 24h IOP levels

CONCLUSIONS: This study suggests that DTFC given with Latanoprost provide a better 24h IOP de-
crease than Latanoprost/Timolol or Dorzolamide/Timolol bitherapies.
215